2021 Revenues ($USD) : $6,763,000,000
2021 R&D spend : $673,000,000
2021 Number of Employees : 23,655
Fiscal Year End : 12/31/2020
Key People : David Endicott, CEO; Laurent Attias, head corporate development, strategy, business development and licensing and mergers and acquisitions; Heather Attra, SVP, head global quality; Jeannette Bankes, president and GM, global surgical franchise; Royce Bedward, SVP, general counsel and corporate secretary; Ian Bell, president, global business and innovation; Sergio Duplan, president, North America; Karen King, SVP, investor relations and communications; Franck Leveiller, SVP, head global R&D; Sue-Jean Lin, SVP, chief information and transformation officer; Kim Martin, SVP, chief human resources officer; Ed McGough, SVP, head global manufacturing and technical operations; Rajkumar Narayanan, president, international; Andy Pawson, president and GM, global vision care franchise; Tim Stonesifer, SVP, CFO.

About the company: Formerly a subsidiary of pharmaceutical giant Novartis since 2011, Alcon officially spun out as a separate eye care business in April 2019. The company was founded in 1945 by Robert Alexander and William Conner as a small pharmacy in Fort Worth, Texas. Its U.S. headquarters remains in Fort Worth today, with global operations run out of its Geneva, Switzerland headquarters. The company’s offerings exist in the surgical and vision care spaces. Alcon develops ophthalmic surgical products, with a portfolio including technologies and devices for cataract, retinal, refractive surgery and advanced technology intraocular lenses to treat conditions like presbyopia and astigmatism. The surgical portfolio also includes advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery, while the vision care business offers a wide range of daily disposable, reusable and color-enhancing contact lenses and a comprehensive portfolio of ocular health products. These include products for dry eye, contact lens care and ocular allergies, as well as ocular vitamins and redness relievers. Alcon made a massive ophthalmic play this year when it announced its intention to acquire glaucoma surgery device maker Ivantis for $475 million upfront.  –SW